Fairmount Funds Management LLC
Top Portfolio Positions
12 positions ·
$1,457,080,670 total
· as of Mar 31, 2026
| Ticker | Company | Shares | Value (USD) | % of Portfolio | Open |
|---|---|---|---|---|---|
| DMRA |
Damora Therapeutics, Inc.
Healthcare
|
8,713,000 | $225,666,700 | 15.49% | |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
2,537,191 | $212,921,068 | 14.61% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
5,503,418 | $211,826,558 | 14.54% | |
| SYRE |
Spyre Therapeutics, Inc.
Healthcare
|
4,018,101 | $202,673,014 | 13.91% | |
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
3,705,262 | $181,743,101 | 12.47% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
3,711,288 | $145,482,488 | 9.98% | |
| VRDN |
Viridian Therapeutics, Inc.DE
Healthcare
|
3,914,458 | $76,566,798 | 5.25% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
4,553,494 | $63,976,590 | 4.39% | |
| CBIO |
Crescent Biopharma, Inc.
Healthcare
|
2,747,866 | $50,478,298 | 3.46% | |
| ZBIO |
Zenas BioPharma, Inc.
Healthcare
|
2,359,025 | $46,118,938 | 3.17% |
Portfolio Trend
25 quarters · across all stocks
Holdings in CBIO
Shares Held
Position Value (USD)
6 quarters on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $50,478,298 | 2,747,866 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $32,589,690 | 2,747,866 | Shares | Sole | 2026-02-17 | |
| 2025-12-04 | $73,308,831 | 5,643,482 | Shares | Sole | 2025-12-08 | |
| 2025-09-30 | $16,501,726 | 1,387,866 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $22,400,157 | 1,387,866 | Shares | Sole | 2025-08-14 | |
| 2025-06-13 | $49,987,520 | 3,124,220 | Shares | Sole | 2025-06-23 | |
| No 13F history on record for this holder in this stock. | ||||||